Erratum to: Sorafenib-Associated Facial Acneiform Eruption[Dermatol Ther (Heidelb), (2014), 5, 1, DOI 10.1007/s13555-014-0067-9];Sorafenib-Associated Facial Acneiform Eruption

Dermatology and Therapy

Volumn 5, Issue 1, 2015, Pages 77-86

  Cohen, Philip R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Acne; Acneiform eruption; Chloracne; Cutaneous adverse events; Hepatocellular carcinoma; Renal cell carcinoma; Skin side effects; Sorafenib

Indexed keywords

ALPHA FETOPROTEIN; BETAMETHASONE DIPROPIONATE; CLINDAMYCIN; DESONIDE; RETINOIC ACID; SORAFENIB;

ACNE; AGED; ALOPECIA; ALPHA FETOPROTEIN BLOOD LEVEL; ANGIONEUROTIC EDEMA; ARTICLE; CASE REPORT; CHEILITIS; CHLORACNE; DARIER DISEASE; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; EPIDERMOID CYST; ERYTHEMA MULTIFORME; EVENING DOSAGE; FACIAL ACNEIFORM ERUPTION; FIXED DRUG ERUPTION; FOLLICULITIS; HAIR LOSS; HAND FOOT AND MOUTH DISEASE; HUMAN; LEUKOCYTOCLASTIC VASCULITIS; LIVER CELL CARCINOMA; LOW DRUG DOSE; MALE; MELANOCYTIC NEVUS; PAPULE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PRURITUS; SEBORRHEIC DERMATITIS; STOMATITIS; TOPICAL TREATMENT; TREATMENT DURATION; VERY ELDERLY;

EID: 84925767839     PISSN: 21938210     EISSN: 21909172     Source Type: Journal    
DOI: 10.1007/s13555-015-0069-2     Document Type: Erratum

References (56)

1. Scandurra G, Aiello RA, Ali M, Taibi E, Sano MV, Todaro FM, La Rocca R, Licciardello P, Caruso M. Appropriate management of cutaneous adverse events maximizes compliance with sorafenib treatment: a single center experience. Future Oncol. 2012;8:609–15 (PMID = 22646774).
2. Lee WJ, Lee JL, Chang SE, Lee MW, Kang YK, Choi JH, Moon KC, Koh JK. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. Br J Dermatol. 2009;161:1045–51 (PMID = 19558553).
3. Vincenzi B, Santini D, Russo A, Addeo R, Guiliani F, Montella L, Rizzo S, Venditti O, Frezza AM, Caraglia M, Colucci G, Del Prete S, Tonini G. Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. Oncologist. 2010;15:85–92 (PMID = 20051477).
4. Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24:2505–12 (PMID = 16636341).
5. Wozel G, Sticherling M, Schon MP: Cutaneous side effects of inhibition of VEGF signal transduction. J DutschDermatolGes 2010;8:243-9 (PMID = 19832927).
6. Pragasam V, Verma R, Vasudevan B. Sorafenib and sunitinib: a dermatologist’s perspective. Indian Dermatol Online J. 2014;5(1):1–3 (PMID = 24616845).
7. Ishak RS, Aad SA, kyel A, Farhat FS. Cutaneous manifestations of anti-angiogenic therapy in oncology: review with focus on VEGF inhibitors. Crit Rev Oncol Hematol. 2014;90:152–64 (PMID = 24355408).
8. Robert C, Soria JC, Spatz A, Le Cesne A, Malka D, Pautier P, Wechsler J, Lhomme C, Escudier B, Boige V, Armand JP, Le Chevalier T. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol. 2005;6:491–500. (PMID = 15992698).
9. Robert C, Mateus C, Spatz A, Wechsler J, Escudier B. Dermatologic symptoms associated with the multikinase inhibitor sorafenib. J Am Acad Dermatol. 2009;60:299–305 (PMID = 19028406).
10. Curry JL, Torres-Cabala CA, Kim KB, Tetzlaff MT, Duvic M, Tsai KY, Hong DS, Prieto VG. Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions. Int J Dermatol. 2014;53:376–84 (PMID = 2387947).
11. McLellan B, Kerr H. Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib. Dermatol Ther. 2011;24:396–400 (PMID = 21910797).
12. Scandurra G, Aiello RA, Ali M, Taibi E, Sano MV, Todaro FM, LaRocca R, Licciardello P, Caruso M. Appropriate management of cutaneous adverse events maximizes compliance with sorafenib treatment: a single-center experience. Future Oncol. 2012;8:609–15 (PMID = 22646774).
13. Lipworth AD, Robert C, Zhu AX. Hand–foot syndrome (hand–foot skin reaction, palmar–plantar erythrodysesthesia): focus on sorafenib and sunitinib. Oncology. 2009;77:257–271 (PMID = 19923864).
14. Yang CH, Lin WC, Chuang CK, Chang YC, Pang ST, Lin YC, Kuo TT, Hsieh JJ, Chang JWC. Hand–foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy. Br J Dermatol. 2008;158:592–596 (PMID = 18070211).
15. Maddox JS, Kung EF, Petronic-Rosic V, Sethi A. Cutaneous drug eruptions induced by sorafenib: a case series. J Drugs Dermatol. 2008;7:891–893 (PMID = 19112807).
16. Autier J, Mateus C, Wechsler J, Spatz A, Robert C. Cutaneous side effects of sorafenib and sunitinib. Ann Dermatol Venereol. 2008;135(7):148–53 [quiz 7, 154 (PMID = 18342102)].
17. Galan Brotons A, Borras-Biasco J, Rosique-Robles JD, Vicent Verge JM, Castera MDE. Generalized erythematous skin eruptions induced by sorafenib: cutaneous toxicity and treatment outcome. Clin Transl Oncol. 2008;10:844–6 (PMID = 19068457).
18. Heidary N, Naik H, Burgin S. Chemotherapeutic agents and the skin: an update. J Am Acad Dermatol. 2008;58:545–70 (PMID = 18342708).
19. Autier J, Escudier B, Wechsler J, Spatz A, Robert C. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. Arch Dermatol. 2008;144:886–92 (PMID = 18645140).
20. Robert C, Faivre S, Raymond E, Armand JP, Escudier B. Subungual splinter hemorrhages: a clinical window to inhibition of vascular endothelial growth factor receptors? [letter] Ann Intern Med. 2005;143:313–4 (PMID = 16103482).
21. Wolber C, Udvardi A, Tatzreiter G, Schneeberger A, Volc-Platzer B. Perforating folliculitis, angioedema, hand–foot syndrome—multiple cutaneous side effects in a patient treated with sorafenib. J Dtsch Dermatol Ges. 2009;7:449–52 (PMID = 19178612).
22. Williams VL, Cohen PR, Stewart DJ. Sorafenib-induced premalignant and malignant skin lesions. Int J Dermatol. 2011;50:396–402 (PMID = 21413947).
23. MacGregor JL, Silvers DN, Grossman ME, Sherman WH: Sorafenib-induced erythema multiforme. [letter] J Am Acad Dermatol. 2007;56:527–28 (PMID = 17241689).
24. Lewin J, Farley-Loftus R, Pomeranz MK. Erythema multiforme-like drug reaction to sorafenib. J Drug Dermatol 2011;10:1462–3 (PMID = 22134572).
25. Bilac C, Muezzinoglu T, Ermertcan AT, Kayhan TC, Temeltas G, Ozturkcan S, Temiz P. Sorafenib-induced erythema multiforme in metastatic renal carcinoma. Cutan Ocul Toxicol. 2009;28:90–2 (PMID = 19514932).
26. Bilac C, Muezzinoglu T, Ermertcan AT, Kayhan TC, Temeltas G, Ozturkcan S, Temiz P. Sorafenib = induced erythema multiforme in metastatic renal cell carcinoma. Cutan Ocul Toxicol. 2009;28:90–92 (PMID = 19514932).
27. Ikeda M, Fujita T, Mii S, Tanabae K-I, Tabata K-I, Matsumoto K, Satoh T, Iwamura M. Erythema multiforme induced by sorafenib for metastatic renal cell carcinoma. Jpn J Clin Oncol. 2012;42:820–4 (PMID = 22782962).
28. Ikeda M, Fujita T, Amoh Y, Mii S, Matsumoto K, Iwamura M. Stevens-Johnson syndrome induced by sorafenib for metastatic renal cell carcinoma. Urol Int. 2013;91:482–3 (PMID = 239649404).
29. Lacouture ME, Desai A, Soltani K, Petronic-Rosic V, Laumann AE, Ratain MJ, Stadlert WM. Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor. Clin Exp Dermatol. 2006;31:783–5 (PMID = 16824050).
30. Kong HH, Turner ML. Array of cutaneous adverse effects associated with sorafenib. J Am Acad Dermatol. 2009;61:360–1 (PMID = 19615549).
31. Cohen PR: Development of cutaneous premalignant lesions and malignant tumors in patients receiving sorafenib [comment on invasive squamous cell carcinoma and sorafenib in a black patient]. JAMA Dermatol. http://archderm.jamanetwork.com/article.aspx?articleid=426443. Posted Feb 13, 2011. Accessed Nov 30, 2014.
32. Hong DS, Reddy SB, Prieto VG, Wright JJ, Tannir NM, Cohen PR, Diwan AH, Evans HL, Kurzrock R. Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib. Arch Dermatol. 2008;144:779–82 (PMID = 18559769).
33. Chappell JA, Burkemper NM, Semchyshyn N. Localized dyskeratotic plaque with milia associated with sorafenib. J Drug Dermatol. 2009;8:573–6 (PMID = 19537383).
34. Ensslin CJ, Rosen AC, Wu S, Lacouture ME. Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysis. J Am Acad Dermatol. 2013;69:708–20 (PMID = 23981682).
35. Bauer C, Przybilla B, Rueff F. Severe cutaneous reaction to sorafenib: induction of tolerance. Acta Derm Venereol. 2008;88:627–8 (PMID = 19002355).
36. Diamantis ML, Chon SY. Sorafenib-induced psoriasiform eruption in a patient with metastatic thyroid carcinoma. J Drugs Dermatol. 2010;9:169–71 (PMID = 20214183).
37. Fleta-Asin B, Vano-Galvan S, Ledo-Rodriguez A, Truchuelo-Diez M, Jaen-Olasolo P. Facial acneiform rash associated with sorafenib. Dermatol Online.J 2009;15(4):7 (PMID = 19450400).
38. Pickert A, Hughes M, Wells M. Chloracne-like drug eruption associated with sorafenib. J Drug Dermatol. 2011;10:1331–4 (PMID = 22052319).
39. Joncas V, Sammour R, Krasny M, Bouffard D, Provost N. A distinctive cutaneous reaction to sorafenib and a multikinase inhibitor. Int J Dermatol. 2008;47:767–9 (PMID = 18613894).
40. Porta C, Paglino C, Imarisio I, Bonomi L. Uncovering Pandora’s vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitnib. Clin Exp Med. 2007;7:127–34 (PMID = 18188524).
41. Alexandrescu DT, Vaillant JG, Dasanu CA. Effect of treatment with a colloidal oatmeal lotion on the acneform eruption induced by epidermal growth factor receptor and multiple tyrosine-kinase inhibitors. Clin Exp Dermatol. 2007;32:71–4 (PMID = 17034418).
42. Duran I, Hotte SJ, HirteH, Chen EX, MacLean M, Turner S, Duan L, Pond GR, Lathia C, Walsh S, Wright JJ, Dancey J, Siu LL. Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumors. Clin Cancer Res. 2007;13:4849-57 (PMID = 17699864).
43. Ji YX, Zhang ZF, Lan KT, Nie KK, Geng CX, Liu SC, Zhang L, Zhuang XJ, Zou X, Sun L, Zhang ZC. Sorafenib in liver function impaired advanced hepatocellular carcinoma. Chin Med Sci J. 2014;29:7–14 (PMID = 24698672).
44. Hotte SJ, Hirte HW: BAY 43-9006. early clinical data inpatients with advanced solid malignancies. Cur Pharm Des. 2002;8:2249–53 (PMID = 12369852).
45. Rubsam K, Flaig MJ, Ruzicka T, Prinz JC: Erythema marginatum hemorrhagicum: a unique side effect of sorafenib. [letter] J Am AcadDermatol 2011;64:1194-1196 (PMID = 21571189).
46. Kong HH, Sibaud V, Chanco Turner ML, et al. Sorafenib-induced eruptive melanocytic lesions. Arch Dermatol. 2008;144:820–2 (PMID = 18559790).
47. Bennani-Lahlou M, Mateus C Escudier B, Massard C, Soria JC, Spatz A, Robert C. Eruptive nevi associated with sorafenib treatment. Ann Dermatol Venereol. 2008;135:672–4 (PMID = 18929917).
48. Chung NM, Gutierrez M, Turner ML. Leukocytoclastic vasculitis masquerading as hand–foot syndrome in a patient treated with sorafenib. Arch Dermatol. 2006;142:1510–11 (PMID = 17116852).
49. Tanabe K, Amoh Y, Mii S, Eto H, Iwamura M, Kasuoka K. Non-pigmented fixed drug eruption induced by sorafenib. Acta Derm Venereol 2010;90:307 (PMID = 20526556).
50. Pichler M, Carriere C, Mazzoleni G, Kluge R, Eisendle K. Acne inversa-like lesions associated with the multi-kinase inhibitor sorafenib. Clin Exp Dermatol. 2014;39:232–3 (PMID = 24330088).
51. Franck N, Barete S, Moguelet P, Blanchet B, Carlotti A, Ropert S, Avril MF, Frances C, Billemont B, Goldwasser F. Spiny follicular hyperkeratosis eruption: a new cutaneous adverse effect of sorafenib. [letter] J Clin Oncol. 2010;28:e640–2 (PMID = 20855839).
52. Magne N, Chargari C, Auberdiac P, Moncharmont C, Merrouche Y, Spano J-P. Ultraviolet recall dermatitis reaction with sorafenib. Invest New Drugs. 2011;29:1111–3 (PMID = 20567994).
53. Dasanu C, Cutcher J, Alexandrescu D. Yellow skin discoloration associated with sorafenib use for treatment of metastatic renal cell carcinoma. South Med J. 2007;100:328–30 (PMID = 17396743).
54. Panteleyev AA, Bickers DR. Dioxin-induced chloracne—reconstructing the cellular and molecular mechanisms of a classic environmental disease. Exp Dermatol. 2006;15:705–30 (PMID = 16881967).
55. Perez-Soler R. Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer. Clin Lung Cancer. 2006;8 Suppl 1:S7–14 (PMID = 17239291).
56. Shomura M, Kagawa T, Shiraishi K, Hirose S, Arase Y, Koizumi J, Mine T. Skin toxicity predicts efficacy to sorafenib in patients with advanced hepatocellular carcinoma. World J Hepatol. 2014;6:670–6 (PMID = 25276283).